Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin – Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – GlobeNewswire November 03, 2025 SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a […]